Our Take
Sinclair is entering a real competition with real money on measurable outcomes, but he's competing against teams whose own whole-animal studies failed from toxicity, and his unpublished animal work sits in a field that still can't agree on how to measure aging.
Why it matters
The XPrize is forcing the longevity field to establish standardized aging biomarkers and safety protocols before any drug regulator will touch whole-body rejuvenation claims. Sinclair's entry signals that chemical reprogramming (not just gene therapy) is where the near-term bets are concentrating.
Do this week
Biotech investors: monitor the August finalist announcement and the trial safety data starting this year; chemical reprogramming toxicity is the real gating factor, not the biology.
Sinclair's XPrize bid: oral chemistry, not gene therapy
Harvard Medical School biologist David Sinclair plans to test an oral drug mixture (code-named SL-100) on human volunteers as part of the $101 million XPrize Healthspan Competition, according to MIT Technology Review. The competition, organized by the XPrize Foundation and funded by Saudi Arabia's Hevolution Foundation, awards cash to teams able to restore a person to an earlier biological age as measured by improvements in immune, cognitive, and muscle function. The grand prize goes to any team showing a 10-year or greater relative improvement after one year of treatment.
Sinclair declined to disclose the exact composition of SL-100, but his prior published work on "epigenetic age-reversal cocktails" mixed vitamins (forskolin), approved drugs (the antidepressant tranylcypromine), and experimental molecules (laduviglusib, tested against Alzheimer's). He says the current formulation is "an improvement and an advance" on earlier six-factor versions. Animal studies remain unpublished. The drug targets epigenetic marks, molecular controls on DNA that determine a cell's identity and metabolism. The mechanism: by chemically mimicking embryonic reprogramming genes, compounds can theoretically reset these marks across the body via the bloodstream.
This is bolder than Sinclair's other current effort. In January 2026, his company Life Biosciences won approval to test gene therapy using reprogramming genes, limited to the eye to treat glaucoma. That trial treated its first patient in June. The XPrize entry seeks whole-body effects via a pill.
The field still cannot measure what it claims to achieve
The XPrize competition itself has a different purpose than validating Sinclair's drug. According to Jamie Justice, the contest's executive director and a medical doctor, a primary goal is to "solve the problem" of how to measure aging reliably. She told FDA officials in May that "if a medicine improves how we age, how would we know? If something worked, what would convince us as scientists, what's meaningful to the general public?"
This is the actual bottleneck. Competing teams, which will be narrowed to 10 finalists in August from 65 entries, are exploring health foods, lifestyle interventions, digital trackers, and drug compounds. Sinclair's team entered late but must start wider human trials this year. Other teams have already hit the toxicity wall. Vadim Gladyshev, a Harvard biologist on a different XPrize team, reported last year that attempts to rejuvenate mice using seven-compound cocktails delivered via implanted pumps proved toxic: "at low concentrations there was no effect, and high concentrations were toxic."
Sinclair has also faced credibility damage. In 2024, he resigned as president of the Academy for Health and Lifespan Research after claiming a supplement developed by his brother's company had "reversed" the age of dogs, a claim one scientist called a "lie." He has been criticized by peers for making unproven rejuvenation claims on social media and in books.
What to watch
The real signal is not whether Sinclair's cocktail works, but whether the XPrize infrastructure forces the field to define what "works" means before money and clinical effort are spent. Standardized biomarkers, transparent toxicity reporting, and independent measurement of age reversal are prerequisites for regulatory approval. Sinclair's team is racing against that clock and against competitors whose own animal work has failed on safety grounds.
James Clement, head of Betterhumans, is running clinical trials of an oral reprogramming cocktail for Sinclair's XPrize team. NewLimit, a startup funded by crypto billionaire Brian Armstrong, raised an additional $435 million on June 2 to develop genetic reprogramming instructions for the liver. The race is real. The science, so far, remains unpublished.